CSBio CSBio

X
[{"orgOrder":0,"company":"Edge Pharma","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Edge Pharma Completes Supplier Agreement with ANI Pharmaceuticals, Inc","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Edge Pharma"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Fosaprepitant for Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Tentative Approval from USFDA for Tofacitinib Extended-Release Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Prednisone Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Strides Pharma Science"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch Of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Authorized Generic Version of Alinia\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caplin Steriles Receives USFDA Approval for Prochlorperazine Edisylate Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Caplin Steriles"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives US FDA Approval for Mesalamine ER Capsules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives US FDA Approval to Market Glycopyrrolate Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Sanzyme","sponsor":"J.B.Chemicals & Pharmaceuticals","pharmaFlowCategory":"D","amount":"$84.0 million","upfrontCash":"Undisclosed","newsHeadline":"JB Chemicals To Acquire Brands from Sanzyme For Rs, 628 Crore","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sanzyme"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Announces the Re-Launch of Over-The-Counter Famotidine Tablets USP, 10 mg and 20 mg, Store-Brand Equivalent of Pepcid AC\u00ae in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark Pharmaceuticals Inc., USA Continues to Expand Its Over-The-Counter (OTC) Portfolio With the Acquisition of Approved ANDAs From Wockhardt Limited","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Wockhardt"},{"orgOrder":0,"company":"Sanzyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Probiotic Strain SNZ 1969\u00ae Helps Manage IBS-D & IBS-C Symptoms Effectively, Latest Clinical Study Shows","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sanzyme"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval From USFDA For Glycopyrrolate Injection USP","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marksans Pharma Limited Announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Marksans Pharma"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg, respectively","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Lubiprostone Capsules, 8 mcg and 24 mcg","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Loperamide Hydrochloride Capsules USP, 2 mg","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Gets USFDA Nod for Generic Drug Used for Short-term Treatment of Heartburn","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Granules India Limited"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.

            Lead Product(s): Lansoprazole

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2021

            Details:

            Prednisone is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Deltasone Tablets, 2.5 mg and 5 mg, of Pharmacia and Upjohn Co.

            Lead Product(s): Prednisone

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Strides Pharma Science

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Dr. Reddy’s OTC Famotidine Tablets USP, 10 mg and 20 mg, are acid reducers that prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.

            Lead Product(s): Famotidine

            Therapeutic Area: Gastroenterology Product Name: Famotidine-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 20, 2020

            Details:

            Esomeprazole magnesium delayed-release capsules is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease and NSAID-associated gastric ulcer.

            Lead Product(s): Esomeprazole Magnesium

            Therapeutic Area: Gastroenterology Product Name: Nexium-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Loperamide hydrochloride binds to the opiate receptor in the gut wall and acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel.

            Lead Product(s): Loperamide Hydrochloride

            Therapeutic Area: Gastroenterology Product Name: Imodium-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. It is indicated for chronic idiopathic constipation and IBS with constipation.

            Lead Product(s): Lubiprostone

            Therapeutic Area: Gastroenterology Product Name: Amitiza-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tofacitinib is a janus kinase (JAK) inhibitor which causes gut inflammation in ulcerative colitis. Thus, by blocking JAK tofacitinib reduces inflammation in UC patients.

            Lead Product(s): Tofacitinib Citrate

            Therapeutic Area: Gastroenterology Product Name: Xeljanz-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Famotidine is an H2 antagonist, it inhibits acid secretion by blocking the action of histamine on the parietal cells, ultimately reducing acid secretion into the stomach.

            Lead Product(s): Famotidine

            Therapeutic Area: Gastroenterology Product Name: Famotidine-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Glycopyrrolate is an anticholinergic agents, competitively inhibit binding of the neurotransmitter, acetylcholine. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.

            Lead Product(s): Glycopyrronium Bromide

            Therapeutic Area: Gastroenterology Product Name: Glycopyrrolate-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Latest study shows Sanzyme Biologics's Bacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in managing IBS symptoms.

            Lead Product(s): Probiotic Strain SNZ 1969

            Therapeutic Area: Gastroenterology Product Name: SNZ 1969

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY